Prophylactic Efficacy of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Women with Virological Evidence of HPV Infection

November 2007
Journal of Infectious Diseases;11/15/2007, Vol. 196 Issue 10, p1438
Academic Journal
Background. A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-particle (VLP) vaccine has been shown to be 95%-100% effective in preventing cervical and genital disease related to HPV-6, -11, -16, and -18 in 16-26-year-old women naive for HPV vaccine types. Because most women in the general population are sexually active, some will have already been infected with ⩾1 HPV vaccine types at the time vaccination is offered. Here, we assessed whether such infected women are protected against disease caused by the remaining HPV vaccine types. Methods. Two randomized, placebo-controlled trials of the quadrivalent (types 6, 11, 16, and 18) HPV vaccine enrolled 17,622 women without consideration of baseline HPV status. Among women infected with 1-3 HPV vaccine types at enrollment, efficacy against genital disease related to the HPV vaccine type or types for which subjects were naive was assessed. Results. Vaccination was 100% effective (95% confidence interval [CI], 79%-100%) in preventing incident cervical intraepithelial neoplasia 2 or 3 or cervical adenocarcinoma in situ caused by the HPV type or types for which the women were negative at enrollment. Efficacy for preventing vulvar or vaginal HPV-related lesions was 94% (95% CI, 81%-99%). Conclusions. Among women positive for 1-3 HPV vaccine types before vaccination, the quadrivalent HPV vaccine protected against neoplasia caused by the remaining types. These results support vaccination of the general population without prescreening.


Related Articles

  • Vaccine is effective against HPV. Harper, D. M.; Franco, E. L.; Wheeler, C. // BMJ: British Medical Journal (International Edition);2/5/2005, Vol. 330 Issue 7486, p264 

    Presents a response to the question of whether or not the vaccine for human papillomavirus strains is associated with cervical cancer. Summary of a study which pointed out the efficacy of the vaccine in reducing HPV infection and cytological abnormalities; Need for a study to see if there is a...

  • Towards the eradication of HPV infection through universal specific vaccination. Crosignani, Piergiorgio; De Stefani, Antonella; Fara, Gaetano Maria; Isidori, Andrea M.; Lenzi, Andrea; Liverani, Carlo Antonio; Lombardi, Alberto; Mennini, Francesco Saverio; Palu, Giorgio; Pecorelli, Sergio; Peracino, Andrea P.; Signorelli, Carlo; Vincenzo Zuccotti, Gian // BMC Public Health;2013, Vol. 13 Issue 1, p1 

    Background: The Human Papillomavirus (HPV) is generally recognized to be the direct cause of cervical cancer. The development of effective anti-HPV vaccines, included in the portfolio of recommended vaccinations for any given community, led to the consolidation in many countries of immunization...

  • A Human Papillomavirus (HPV) Vaccine on the Horizon. Deresinski, Stan // Clinical Infectious Diseases;2/15/2005, Vol. 40 Issue 4, preceding p1 

    This article reports that chronic infection with high risk human papillomaviruses (HPVs) has been implicated in virtually all cervical cancers. Two HPV types, HPV-16 and HPV-18, together account for 70% of cases of cervical cancer. HPV is also a cause of a variety of other cancers, including...

  • HPV vaccine could block precancerous lesions.  // GP: General Practitioner;4/15/2005, p25 

    The article reports that an human papillomavirus (HPV) vaccine in development completely blocks precancerous cervical lesions and genital warts associated with the four most common HPV types. The tested vaccine protects against HPV types 6, 11, 16 and 18. The researchers gave the vaccine to 277...

  • Ensuring access to HPV vaccines through integrated services: a reproductive health perspective. Pollack, Amy E.; Balkin, Miranda; Edouard, Lindsay; Cutts, Felicity; Broutet, Nathalie // Bulletin of the World Health Organization;Jan2007, Vol. 85 Issue 1, p57 

    In 2006, a quadrivalent human papillomavirus (HPV) vaccine was licensed, and another vaccine may be licensed soon. Little is known about the practical considerations involved in designing and implementing cervical cancer prevention programmes that include vaccination as a primary means of...

  • Vaccines against cervical cancer provoke US controversy. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);4/8/2006, Vol. 332 Issue 7545, p814 

    The article focuses on a new vaccine for cervical cancer which is inciting controversy in the United States from conservative groups concerned that it should not be given to 11 and 12-year-old children, as it may encourage sexual activity. The function of the vaccine, which targets the sexually...

  • What If Preventing Cancer Is as Easy as Being Vaccinated? Biedrzycki, Barbara A. // ONS News;Aug2006, Vol. 21 Issue 8, p9 

    The article reports on the development of a human papillomavirus (HPV) vaccine intended for the prevention of cervical cancer among men and women worldwide. HPV has been sought to be the most common sexually transmitted disease with 20 million men and women have been infected. With the approval...

  • HPV and Cervical Cancer. Leaver, Dennis; Labonte, Geri // Radiation Therapist;Spring2010, Vol. 19 Issue 1, p27 

    Human papillomaviruses (HPVs) are estimated to cause a half million cases of cervical cancer worldwide each year. This article reviews the connection between HPVs and cervical cancer, discusses the HPV vaccine and provides an overview of cervical cancer symptoms, staging and treatment. Case...

  • Human Papilloma Virus and HPV vaccine knowledge among Mustafa Kemal University Medical Students. Keskin Kurt, Raziye; Karateke, Atilla; Erdem, Mehmet; Benk Silfeler, Dilek; Nesrin Akkoca, Ayse; Soylu Karapinar, Oya; Ulvi Hakverdi, Ali // Acta Medica Anatolia;2014, Vol. 2 Issue 2, p37 

    Objectives: Human papilloma virus (HPV) is regarded as the main cause in the etiology of cervical cancer. The purpose of our study is to assess the knowledge of medical students about HPV vaccine and to evaluate their opinion on this subject. Methods: The study population consisted of 488...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics